Profitability
Weight: 20%
F
4
- 5yr Avg ROIC -2.2%
- Operating Margin Trend -6.35 pp/yr
CTKB
Cytek Biosciences, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 28.1 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
D-
29
- 5yr Avg ROE -4.6%
- 5yr Share-Count CAGR -1.1%
Growth Quality
Weight: 15%
C+
58
- 5yr Revenue CAGR 12.0%
- 5yr EPS CAGR -43.6%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 15%
F
10
- 5yr FCF Margin -1.3%
- 5yr FCF/NI Conversion -4.25x
Balance Sheet
Weight: 20%
F
21
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -61.96x
- Altman Z-Score 3.17
Stability
Weight: 15%
C+
58
- EPS Volatility (σ/μ) 0.29
- Piotroski F-Score 2
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 trimmed; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- -1.1%
- New buys
- 0
- Full exits
- 1